The discovery that CD47 expression is often increased on the surface of cancer cells, and CD47’s role as a ‘don’t eat me’ signal for phagocytes, have led to significantly heightened interests in the development of neutralizing antibody-based therapeutics targeting the CD47-SIRPα interaction. The gene discussed is CD47; the disease is cancer.